<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Zuo-Tao</forename><surname>Zhao</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Chun-Mei</forename><surname>Ji</surname></persName>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Pharm</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">the Research Division of Clinical Pharmacology</orgName>
								<orgName type="department" key="dep2">Department of Cadre Health Care</orgName>
								<orgName type="institution">First Affiliated Hospital of Nanjing Medical University</orgName>
								<address>
									<settlement>Nanjing</settlement>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Jiangsu Province Geriatric Institution</orgName>
								<orgName type="institution" key="instit2">Jiangsu Province Official Hospital</orgName>
								<address>
									<settlement>Nanjing</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">the Research Division of Clinical Pharmacology</orgName>
								<orgName type="department" key="dep2">Department of Cadre Health Care</orgName>
								<orgName type="institution">First Affiliated Hospital of Nanjing Medical University</orgName>
								<address>
									<settlement>Nanjing</settlement>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Jiangsu Province Geriatric Institution</orgName>
								<orgName type="institution" key="instit2">Jiangsu Province Official Hospital</orgName>
								<address>
									<settlement>Nanjing</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Wen-Jun</forename><surname>Yu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ling</forename><surname>Meng</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Tomasz</forename><surname>Hawro</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Ji-Fu</forename><surname>Wei</surname></persName>
							<email>weijifu@hotmail.com</email>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">the Research Division of Clinical Pharmacology</orgName>
								<orgName type="department" key="dep2">Department of Cadre Health Care</orgName>
								<orgName type="institution">First Affiliated Hospital of Nanjing Medical University</orgName>
								<address>
									<settlement>Nanjing</settlement>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Jiangsu Province Geriatric Institution</orgName>
								<orgName type="institution" key="instit2">Jiangsu Province Official Hospital</orgName>
								<address>
									<settlement>Nanjing</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Marcus</forename><surname>Maurer</surname></persName>
							<email>marcus.maurer@charite.de</email>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">Beijing and Nanjing</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country>China, Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Dermatology and Venereology</orgName>
								<orgName type="department" key="dep2">First Hospital</orgName>
								<orgName type="institution">Peking University</orgName>
								<address>
									<settlement>Beijing</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<orgName type="institution">Allergie-Centrum-Charit e</orgName>
								<address>
									<settlement>Charit e-Universit€ atsmedizin Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Research Division of Clinical Pharmacology</orgName>
								<orgName type="institution">the First Affiliated Hospital of Nanjing Medical University</orgName>
								<address>
									<postCode>210029</postCode>
									<settlement>Nanjing</settlement>
									<region>Jiangsu</region>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<orgName type="institution">Allergie-Centrum-Charit e</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Charit e-Universit€ atsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">D11FC81602A69668AA6FF8D1B4AEB613</idno>
					<idno type="DOI">10.1016/j.jaci.2015.12.1342</idno>
					<note type="submission">Received for publication September 4, 2015; revised November 16, 2015; accepted for publication December 29, 2015. Available online March 31, 2016.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:23+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Omalizumab</term>
					<term>meta-analysis</term>
					<term>CSU</term>
					<term>weekly itch score</term>
					<term>weekly wheal score</term>
					<term>adverse event</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Chronic spontaneous urticaria (CSU) is defined by itchy hives, angioedema, or both for at least 6 weeks.</s><s>Omalizumab, an anti-IgE antibody that affects mast cell and basophil function, is a promising new treatment option.</s><s>As of now, however, the efficacy and safety of different doses of omalizumab used in clinical trials for CSU have not been systematically analyzed and summarized.</s><s>Objective: We sought to assess the efficacy and safety of different doses of omalizumab for the treatment of CSU in a meta-analysis of clinical trial results.</s><s>Methods: Suitable trials were identified by searching PubMed, Medline, Embase, and Web of Science databases and with the help of omalizumab's manufacturers.</s><s>Only double-blind, randomized, placebo-controlled studies with omalizumabtreated versus placebo-treated patients with CSU were included in this analysis.</s><s>Results: We identified 7 randomized, placebo-controlled studies with 1312 patients with CSU.</s><s>Patients treated with omalizumab (75-600 mg every 4 weeks) had significantly reduced weekly itch and weekly wheal scores compared with the placebo group.</s><s>Omalizumab's effects were dose dependent, with the strongest reduction in weekly itch and weekly wheal scores observed with 300 mg.</s><s>Rates of complete response were significantly higher in the omalizumab group (relative risk, 4.55; P &lt; .00001)</s><s>and dose dependent, with the highest rates in the 300-mg group.</s><s>Rates of patients with adverse events were similar in the omalizumab and placebo groups.</s><s>Conclusion: This meta-analysis provides high-quality evidence for the efficacy and safety of omalizumab in patients with CSU and for treating these patients with 300 mg of omalizumab every 4 weeks.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abbreviations used</head><p><s>AE: Adverse event CSU: Chronic spontaneous urticaria RCT: Randomized, placebo-controlled trial RR: Relative risk UAS7: Urticaria activity score 7 WIS: Weekly itch score WMD: Weighted mean difference WWS: Weekly wheal score Over the past years, omalizumab, which was licensed in 2014 for the treatment of patients with antihistamine-refractory CSU, has emerged as a very effective treatment option for CSU.</s><s>The evidence for this comes from clinical experience; case reports <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b10">11</ref> ; case series <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b19">[14]</ref><ref type="bibr" target="#b20">[15]</ref> ; observational studies; proof-of-concept studies <ref type="bibr" target="#b21">16</ref> ; multicentric randomized, placebo-controlled trials (RCTs) <ref type="bibr" target="#b22">[17]</ref><ref type="bibr" target="#b23">[18]</ref><ref type="bibr" target="#b24">[19]</ref><ref type="bibr" target="#b25">[20]</ref><ref type="bibr" target="#b26">[21]</ref> ; and a recent systematic review and GRADE assessment. <ref type="bibr" target="#b27">22</ref></s><s>Until now, the efficacy and safety of the different doses of omalizumab used in RCTs for the treatment of CSU have not been systematically analyzed, compared, and summarized.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Search strategy and inclusion criteria</head><p><s>A systematic search of PubMed, Medline, Embase, and Web of Science from January 2001 to May 2015 using the search terms ''omalizumab'' and ''urticaria'' was conducted.</s><s>Additionally, Genentech and Novartis were contacted to obtain data from completed trials that are not yet listed in these databases.</s><s>By using a 2-step approach, all of the studies identified by using this strategy were reviewed independently by 2 investigators (CMJ and WJY), and those that met all inclusion criteria were included in our meta-analysis.</s><s>The inclusion criteria were as follows: (1) patients given a diagnosis of CSU and treated with omalizumab; (2) double-blind, randomized, placebo-controlled studies; (3) outcome measures included weekly itch scores (WISs) and weekly wheal scores (WWSs), as well as rates of responders and patients with adverse events (AEs).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Testing for heterogeneity and publication bias of studies</head><p><s>To assess the heterogeneity of the studies included in this meta-analysis, we used the Q test, which is commonly used and considered to show statistically significant differences if P values are less than .1,</s><s>and the I 2 test, which measures the proportion of overall variation attributable to between-study heterogeneity (range, 0% to 100%; &gt;50% indicates evidence of heterogeneity). <ref type="bibr" target="#b28">23</ref></s><s>The Galbraith plot was used to delineate which study was the cause of the heterogeneity.</s><s>Each study is represented by a single dot, with a central regression line through the plot.</s><s>The log-transformed effect size divided by its SE (z score) is shown on the y-axis, and the inverse of the SE is shown on the x-axis.</s><s>Also, we assessed the methodological quality of the included trials and the risk of bias by using elements included in the Cochrane collaboration tool for assessing risk of bias.</s><s><ref type="bibr" target="#b31">[26]</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data extraction and outcome measures</head><p><s>For our meta-analysis, we extracted the following predefined variables: authors, year of publication, study type, name of the study, clinicaltrials.gov</s><s>number, omalizumab doses used, numbers of omalizumab-treated patients and control subjects, duration of study periods, and outcome measures.</s><s>The focus of our analysis was to compare the treatment effects of different doses of omalizumab and placebo across studies.</s><s>The outcomes included in our meta-analysis were the WIS, the WWS, the rate of complete responders (using an urticaria activity score 7 [UAS7] of 0 as the definition of response), and the rate of patients with AEs (&gt; _1 AE).</s></p><p><s>For all included studies, efficacy outcomes data (weighted mean difference [WMD] WIS, WMD WWS, and rate of responders) for week 12 of treatment were analyzed, except for MYSTIQUE (data from week 4 were used).</s><s>For the analysis and comparison of safety outcome (rate of patients with &gt; _1 AE), data from the entire respective treatment periods were used (see Table <ref type="table" target="#tab_3">E1</ref> in this article's Online Repository at www.jacionline.org).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>From the studies included in this analysis, we extracted, for the different doses of omalizumab and placebo, (1) the WMD of the WIS, (2) the WMD of the WWS, (3) the number of responders, and (4) the relative risk (RR) for the occurrence of at least 1 AE (along with the corresponding 95% CI).</s><s>The overall summary effect sizes were estimated with fixed-and random-effects models.</s><s>A P value of less than .05</s><s>was considered statistically significant.</s><s>Review Manager (RevMan version 5.2.5;</s><s>Nordic Cochrane Centre, Copenhagen, Denmark) and STATA (version 12.0; StataCorp, College Station, Tex) software were used for statistical analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study characteristics</head><p><s>We identified 202 potentially relevant studies, of which 190 were excluded based on the review of information provided in the title and abstract of the publications (step 1).</s><s>The most common reasons for exclusion were that studies (1) had no direct relationship with the efficacy and safety of omalizumab in patients with CSU (n 5 79); (2) did not report relevant clinical outcomes (n 5 28); (3) were reviews or meta-analyses (n 5 51); and (4) were not RCTs (n 5 32).</s><s>Full text reviews of the remaining 12 studies (step 2) resulted in exclusion of 5 studies because they lacked appropriate control groups.</s><s>20]<ref type="bibr" target="#b26">[21]</ref><ref type="bibr" target="#b32">27,</ref><ref type="bibr" target="#b33">28</ref> These 7 RCTs enrolled 1230 participants in total.</s><s>Among them, 888 patients were treated with omalizumab, and the other 342 participants were given placebo.</s><s>The characteristics of the 7 selected studies are shown in Table <ref type="table" target="#tab_1">I</ref>. <ref type="bibr" target="#b22">[17]</ref><ref type="bibr" target="#b23">[18]</ref><ref type="bibr" target="#b24">[19]</ref><ref type="bibr" target="#b25">[20]</ref><ref type="bibr" target="#b26">[21]</ref><ref type="bibr" target="#b32">27,</ref><ref type="bibr" target="#b33">28</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk of bias assessment</head><p><s>All of the 7 studies included in the meta-analysis showed a low risk of bias (Fig <ref type="figure" target="#fig_2">2, A</ref>).</s><s>They all used random sequence generation and allocation concealment.</s><s>Blinding of study subjects and investigators was universally maintained by the use of placebo.</s><s>All of the outcome data in the included studies were subjective; their baselines were similar.</s><s>No evidence for publication bias was detected by using the Begg funnel plot (Fig 2 <ref type="figure">, B</ref>) or Egger test (P 5 .228).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effects of omalizumab treatment on WISs and WWSs</head><p><s>All the included studies, including 888 randomized omalizumab-treated patients, were analyzed for the effects of omalizumab treatment and the different doses of omalizumab on WISs and WWSs.</s><s>Overall, when compared with placebo, omalizumab was more effective in reducing WISs (WMD, 24.10; 95% CI, 25.18 to 23.03; P &lt;.00001) and WWSs (WMD, 24.59; 95% CI, 25.29 to 23.88; P &lt; .00001).</s></p><p><s>Analyses of different doses of omalizumab showed that 300 mg was the most effective dose and significantly improved itch and wheal responses compared with placebo, without significant heterogeneity (Fig</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Rate of complete response</head><p><s>In the 7 studies 266 of 1223 patients showed a complete response (ie, a posttreatment UAS7 score of 0).</s><s>Of these complete responders, 245 had received omalizumab (RR, 4.55; 95% CI, 3.33-6.23;</s><s>P &lt;.00001; Fig <ref type="figure" target="#fig_4">3, C</ref>, and Table <ref type="table" target="#tab_2">II</ref>).</s><s>The rates of complete response were 12.6% (RR, 2.04; 95% CI, 1.04-4.01;</s><s>P 5 .04),</s><s>18.3% (RR, 2.70; 95% CI, 1.42-5.12;</s><s>P 5 .002),</s><s>36% (RR, 6.55; 95% CI, 4.17-10.28;</s><s>P &lt; .00001),</s><s>and 33% (RR, 12.08; 95% CI, 1.96-74.47;</s><s>P 5 .007)</s><s>for patients treated with 75, 150, 300, and 600 mg of omalizumab, respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AEs</head><p><s>Across all studies, 880 of 1208 randomized patients experienced 1 or more AEs, with similar rates in omalizumab-treated (73%) and placebo-treated (69%) patients (RR, 1.07; 95% CI, 1.00-1.40;</s><s>P &gt; _ .05;</s><s>Fig <ref type="figure" target="#fig_5">4 and Table II</ref>).</s><s>In the 75-, 150-, 300-, and 600-mg omalizumab groups the rates of patients with 1 or more AEs were 61.7% (RR, 1.02; 95% CI, 0.87-1.19;</s><s>P 5 .85),</s><s>77.4% (RR, 1.19; 95% CI, 1.04-1.36;</s><s>P 5 .01),</s><s>75.6% (RR, 1.05; 95% CI, 0.96-1.15;</s><s>P 5 .28),</s><s>and 51.9% (RR, 0.90; 95% CI, 0.58-1.40;</s><s>P 5 .63),</s><s>respectively.</s><s>The most common AEs across all studies and treatment groups were upper respiratory tract infection, headache, nasopharyngitis, skin and subcutaneous disorders, and gastrointestinal disorders.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Test of heterogeneity and subgroup analyses</head><p><s>When we used metaregression to explore potential sources of heterogeneity of overall results.</s><s>We found that the dose of omalizumab (75, 150, 300, or 600 mg) significantly contributed to the heterogeneity of results (P 5 0.001), but the time point of assessment (4 or 12 weeks after start of treatment, P 5 .509), the UAS7 version used (UAS7 or modified UAS7, P 5 .163),</s><s>or the year of publication (2011, 2013, 2014, and 2015; P 5 .389)</s><s>did not.</s><s>Using the Galbraith radial plot, we found that the results obtained in the group receiving 75 mg of omalizumab in the ASTERIA II trial were the major source of heterogeneity (Fig <ref type="figure">5</ref>).</s><s>We also confirmed that the differences in time points of assessment or the UAS7 version did not significantly affect our analyses by subgroup.</s><s>We did not observe statistically significant differences between MYSTIQUE (assessment of outcome after 4 weeks) and the other studies (assessment of outcome after 12 weeks, Table <ref type="table" target="#tab_2">II</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>and see Fig E1 in this article's Online</head><p><s>Repository at www.jacionline.org).</s><s>We also did not observe statistically significant differences between the 2 studies that used the UAS7 as recommended by the international urticaria guideline and the other studies, which used a modified UAS7 (Table <ref type="table" target="#tab_2">II and</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>This meta-analysis investigated the efficacy and safety of different doses of omalizumab in the treatment of patients with CSU across 7 RCTs.</s><s>Omalizumab was found to be consistently more effective than placebo and to show a placebo-like safety profile.</s><s>The efficacy of omalizumab was found to be dose dependent, and 300 mg was the most effective dose reported.</s><s>To our knowledge, this is the first systematic analysis and comparison of RCT data on the use of different doses of omalizumab for the treatment of CSU.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Choice of reported outcomes that were included in this meta-analysis</head><p><s>WISs and WWSs were used to assess and compare the efficacy of omalizumab and placebo, as well as of different omalizumab doses across studies.</s><s>Itch intensity and wheal numbers are established outcomes for the assessment of CSU treatment effects and are used to calculate the urticaria activity score, the guidelinerecommended tool for measuring disease activity and treatment responses in patients with CSU.</s><s>Of note, 2 slightly different WWSs were used in the 7 studies evaluated.</s><s>Although XCUISITE and MOA used the WWS recommended by the international guidelines (ie, once-daily documentation; score of 1 5 1 to &lt;20 wheals, score of 2 5 20-50 wheals, and score of 3 5 &gt;50 wheals), the MYSTIQUE, ASTERIA, GLACIAL, and X-ACT studies used a modified score (ie, the mean of twice-daily documentation and score values of 1, 2, and 3, indicating 1-6 wheals, 7-12 wheals, and &gt;12 wheals, respectively).</s><s>For our meta-analysis, we presumed that both scores yield similar results, which is supported by the results of our subgroup analysis.</s></p><p><s>The third efficacy outcome we analyzed was the number of complete responders.</s><s>This was done because (1) this responder analysis provides a different look at the efficacy of omalizumab that complements the assessment of mean changes in disease activity, (2) it allows physicians to anticipate the success rates of treatment with different doses of omalizumab, and (3) the studies consistently reported this outcome.</s><s>Of note, the studies analyzed used and reported different responder definitions.</s><s>For example, for week 24 of treatment, the XCUISITE trial reported data on 4 responder populations (weekly sum scores 5 0 for hives, erythema, itch, and angioedema).</s><s>The MYSTIQUE trial reported the number of patients who showed 100%, 90%, 80%, or 70% improvement in UAS7 values during the fourth week after omalizumab treatment.</s><s>In the ASTERIA and GLACIAL studies responders were defined as patients with a UAS7 of 0 or a UAS7 of 6 or less in week 12 after the initiation of treatment.</s></p><p><s>We chose to also analyze the numbers of patients with 1 or more AEs because this is the safety information most relevant to treating physicians.</s><s>Six hundred forty-four (73%) of 888 patients treated with omalizumab and 236 (69%) of 342 patients treated with placebo experienced 1 or more AEs across all studies, which confirms that omalizumab has a placebo-like safety profile.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy of omalizumab and dose dependency of effects</head><p><s>Across all studies, omalizumab treatment overall significantly reduced and controlled CSU symptoms compared with placebo.</s><s>Also, significantly more omalizumab-than placebotreated patients showed symptom relief, as assessed by using responder analyses.</s><s>These findings support the efficacy of treatment of patients with CSU with omalizumab.</s><s>Our results also indicate that the 300-mg dose of omalizumab is consistently the most effective in reducing WISs and WWSs in patients with CSU, as well as the one with the highest rate of complete responders (36%).</s><s>Importantly, this finding does not rule out that individual patients who do not respond to 300 mg of omalizumab can benefit from greater than 300-mg doses of omalizumab.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety of omalizumab</head><p><s>The results of our meta-analysis show that the incidence of AEs is not significantly different between omalizumab-and placebotreated patients with CSU.</s><s>Omalizumab was well tolerated, and most AEs in omalizumab-treated patients reported in the included studies were mild or moderate.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consistency/variability of results across the studies</head><p><s>One of the reasons why meta-analyses are important is that they assess, across different studies, the consistency and variability of results.</s><s>We found that the results of 7 independent studies showed low heterogeneity and high reproducibility, despite the fact that they were done in patient populations that differed in disease severity, pretreatment requirements, frequency of angioedema, and other features.</s><s>This underlines that omalizumab's effects in patients with CSU are robust and reproducible.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strengths and limitations</head><p><s>The strength of our study is that it included the data of more than 800 patients with CSU treated with omalizumab in 7 studies.</s><s>Several limitations should be kept in mind, most importantly the fact that the results of this analysis cannot be extrapolated to populations with chronic urticaria other than those studied in the trials we included, such as patients with chronic inducible urticaria, patients with CSU with angioedema but without wheals (known also as idiopathic angioedema), or patients with CSU of ethnicities other than white.</s><s>Further studies are needed to explore the efficacy and safety of omalizumab in these patient populations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>To conclude, omalizumab treatment of CSU, across all RCTs performed thus far, is effective and safe, and the results of this meta-analysis back the recommendation to treat patients with CSU with 300 mg of omalizumab every 4 weeks.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIG 1 .</head><label>1</label><figDesc><div><p><s>FIG 1. Study selection process.</s><s>We identified 202 potentially relevant studies, of which 7 were included in the meta-analysis.</s></p></div></figDesc><graphic coords="3,99.27,65.60,382.76,365.61" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>see Fig E2).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>FIG 2 .</head><label>2</label><figDesc><div><p><s>FIG 2. Studies included in this meta-analysis show a low risk of bias.</s><s>A, Risk of bias summary for each included study.</s><s>B, Begg funnel plot.</s><s>The largest studies are plotted near the average, and smaller studies are spread evenly on both sides of the average, creating a roughly funnel-shaped distribution.</s><s>Deviation from this shape can indicate publication bias.</s><s>The funnel plot and Egger test showed no evidence of publication bias.</s></p></div></figDesc><graphic coords="4,54.71,65.59,479.48,255.29" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>FIG 3 .</head><label>3</label><figDesc><div><p><s>FIG 3. Meta-analysis of efficacy outcomes of 7 RCTs with omalizumab-and placebo-treated patients with CSU.</s><s>A, WMD WIS.</s><s>B, WMD WWS.</s><s>C, Rates of complete responders (UAS7 5 0) and RRs of complete response.</s><s>Horizontal lines represent 95% CIs of the RR estimates.</s><s>Diamonds represent the meta-analysis summary effect estimate; green dots represent the WMD, and blue dots represent the RR.</s></p></div></figDesc><graphic coords="5,107.66,65.59,365.73,635.87" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>FIG 3 .</head><label>3</label><figDesc><div><p><s>FIG 3. (Continued).</s></p></div></figDesc><graphic coords="6,109.08,65.59,370.75,378.26" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>FIG 4 .</head><label>4</label><figDesc><div><p><s>FIG 4. Meta-analysis of the RCTs comparing rates of patients with at least 1 AE between the omalizumaband placebo-treated groups.</s><s>Horizontal lines represent 95% CIs of the RR estimates.</s><s>Diamonds represent the meta-analysis summary effect estimate, and blue dots represent the RR.</s></p></div></figDesc><graphic coords="7,75.35,270.54,430.56,432.11" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>FIG E2 .</head><label>E2</label><figDesc><div><p><s>FIG E2.</s><s>Subgroup analysis of UAS standard.</s><s>A, WIS.</s><s>B, Weekly hive score.</s><s>Horizontal lines represent 95% CIs of RR estimates.</s><s>Diamonds represent the meta-analysis summary effect estimate; green dots represent WMDs.</s></p></div></figDesc><graphic coords="12,90.54,65.59,407.72,543.01" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>3, A, and Table II: WIS WMD, 25.72; 95% CI, 26.65 to 24.79;</s><s>I 2 5 0%; P &lt; .00001;</s><s>Fig 3, B, and Table II: WWS WMD, 26.18; 95% CI, 27.24 to 25.11;</s><s>I 2 5 0%; P &lt; .00001).</s><s>Omalizumab, 150 and 75 mg, as well as 600 mg, was found to be less effective, although it was significantly better than placebo.</s><s>In the 150-mg subgroup, the WMDs of the WISs and WWSs were 22.94 (95% CI, 24.15 to 21.74;</s><s>I 2 5 0%; P &lt; .00001)</s><s>and 23.97 (95% CI, 25.37 to 22.56; I 2 5 0%; P &lt; .00001),</s><s>respectively.</s><s>In patients treated with 75 mg of omalizumab, the WMD of the WIS was 21.70 (95% CI, 22.90 to 20.50;</s><s>I 2 5 0%; P 5 .001)</s><s>and the WMD of the WWS was 22.35 (95% CI, 23.77 to 20.93;</s><s>I 2 5 0%; P 5 .001).</s><s>In the 600-mg</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE I .</head><label>I</label><figDesc><div><p><s>Characteristics of the RCTs subjected to meta-analysis</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Doses of omalizuma-</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Authors</cell><cell>Year</cell><cell>Type</cell><cell>Study name</cell><cell>CTG</cell><cell>bused (mg)</cell><cell>No.</cell><cell>Treatment (in wk)</cell><cell>Follow-up (wk)</cell></row><row><cell>Maurer et al 17</cell><cell>2011</cell><cell>mRCT</cell><cell>XCUISITE</cell><cell>NCT00481676</cell><cell>150, 300, 600/2 or 4 wk</cell><cell>27/22</cell><cell>24</cell><cell>24</cell></row><row><cell>Saini et al 18</cell><cell>2011</cell><cell>mRCT</cell><cell>MYSTIQUE</cell><cell>NCT00130234</cell><cell>75, 300, 600 once</cell><cell>69/21</cell><cell>4</cell><cell>12</cell></row><row><cell>Maurer et al 19</cell><cell>2013</cell><cell>mRCT</cell><cell>ASTERIA I</cell><cell>NCT01292473</cell><cell>75, 150, 300/4 wk</cell><cell>243/79</cell><cell>12</cell><cell>16</cell></row><row><cell>Kaplan et al 20</cell><cell>2013</cell><cell>mRCT</cell><cell>GLACIAL</cell><cell>NCT01264939</cell><cell>300/4 wk</cell><cell>252/84</cell><cell>24</cell><cell>16</cell></row><row><cell>Saini et al 21</cell><cell>2015</cell><cell>mRCT</cell><cell>ASTERIA II</cell><cell>NCT01287117</cell><cell>75, 150, 300/4 wk</cell><cell>319/80</cell><cell>24</cell><cell>16</cell></row><row><cell>Staubach et al 27</cell><cell>2015</cell><cell>mRCT</cell><cell>X-ACT</cell><cell>NCT01723072</cell><cell>300/4 wk</cell><cell>17/8</cell><cell>28</cell><cell>8</cell></row><row><cell>Metz et al 28</cell><cell>2015</cell><cell>mRCT</cell><cell>MOA</cell><cell>NCT01599637</cell><cell>300/4 wk</cell><cell>44/47</cell><cell>12</cell><cell>8</cell></row><row><cell cols="4">All studies were CSU/chronic idiopathic urticaria studies.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">CTG, clinicaltrials.gov identification number; mRCT, multicenter RCT.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>group the WMDs of the WISs and WWSs were 24.69 (95% CI, 29.05 to 23.03;</s><s>I 2 5 51%; P 5 .04)</s><s>and 24.74 (95% CI, 27.68 to 21.80;</s><s>I 2 5 0%; P 5 .002),</s><s>respectively.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE II .</head><label>II</label><figDesc><div><p><s>Meta-analysis of the RCTs comparing efficacy and safety between the omalizumab and placebo groups Modified urticaria activity score; Po, percentages of at least 1 AE of the omalizumab group; Pp, percentages of at least 1 AE of the placebo group; Ro, rate of complete responders of the omalizumab group; Rp, rate of complete responders of the omalizumab group.</s><s>*Number of comparisons.</s><s>Random effects estimate.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>Cases/</cell><cell>WIS</cell><cell></cell><cell>WWS</cell><cell></cell><cell cols="2">UAS7 score 5 0</cell><cell></cell><cell>&gt; _1 AE</cell><cell></cell></row><row><cell></cell><cell></cell><cell>control</cell><cell></cell><cell>I 2</cell><cell></cell><cell>I 2</cell><cell></cell><cell>I 2</cell><cell></cell><cell></cell><cell>I 2</cell></row><row><cell>Variables</cell><cell>No.*</cell><cell>subjects</cell><cell>WMD (95% CI)</cell><cell>(%)</cell><cell>WMD (95% CI)</cell><cell>(%)</cell><cell>RR (95% CI)</cell><cell cols="2">(%) Ro/Rp (%)</cell><cell>RR (95% CI)</cell><cell>(%)</cell><cell>Po/Pa</cell></row><row><cell>Total dose</cell><cell cols="3">15 885/744 24.10 (25.18 to 23.03)</cell><cell cols="2">63 24.59 (25.29 to 23.88)</cell><cell>42</cell><cell>4.55 (3.33 to 6.23)</cell><cell>26</cell><cell cols="2">27.7/5.3 1.07 (1.00 to 1.40)</cell><cell cols="2">0 72.5/69.0</cell></row><row><cell>75 mg</cell><cell cols="3">3 175/180 21.70 (22.90 to 20.50)</cell><cell cols="2">22 22.35 (23.77 to 20.93)</cell><cell>0</cell><cell>2.04 (1.04 to 4.01)</cell><cell>0</cell><cell cols="4">12.6/6.1 1.02 (0.87 to 1.19) 49 61.7/61.6</cell></row><row><cell>150 mg</cell><cell cols="3">3 177/181 22.94 (4.15 to 21.74)</cell><cell cols="2">0 23.97 (25.37 to 22.56)</cell><cell>0</cell><cell>2.70 (1.42 to 5.12)</cell><cell>0</cell><cell cols="4">18.3/6.6 1.19 (1.04 to 1.36) 13 77.4/66.3</cell></row><row><cell>300 mg</cell><cell cols="3">7 506/340 25.72 (26.65 to 24.79)</cell><cell cols="2">0 26.18 (27.24 to 25.11)</cell><cell>0</cell><cell>6.55 (4.17 to 10.28)</cell><cell>0</cell><cell cols="2">36.0/5.6 1.05 (0.96 to 1.15)</cell><cell cols="2">0 75.6/69.0</cell></row><row><cell>600 mg</cell><cell>2</cell><cell cols="2">27/43 24.69 (29.05 to 20.33)</cell><cell cols="2">51 24.74 (27.68 to 21.80)</cell><cell cols="2">0 12.08 (1.96 to 74.47)</cell><cell>0</cell><cell cols="2">33.3/2.3 0.90 (0.58 to 1.40)</cell><cell cols="2">0 51.8/67.4</cell></row><row><cell>Time point</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>4 wk</cell><cell>3</cell><cell cols="2">69/63 23.24 (25.92 to 20.56)</cell><cell cols="2">59 24.57 (27.58 to 21.55)</cell><cell cols="2">56 10.65 (2.07 to 54.76)</cell><cell>0</cell><cell>-</cell><cell>0.91 (0.63 to 1.33)</cell><cell>0</cell><cell>-</cell></row><row><cell>12 wk</cell><cell cols="3">12 816/681 24.31 (25.52 to 23.10)</cell><cell cols="2">66 24.58 (25.34 to 23.83)</cell><cell>44</cell><cell>4.34 (3.15 to 5.97)</cell><cell>35</cell><cell>-</cell><cell>1.08 (1.01 to 1.16)</cell><cell>0</cell><cell>-</cell></row><row><cell>UAS</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>UAS7</cell><cell>5</cell><cell cols="2">39/74 25.79 (28.07 to 23.05)</cell><cell cols="2">45 25.18 (27.77 to 22.60)</cell><cell>0</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell cols="7">mUAS7 10 846/670 23.76 (24.89 to 22.64) 66 24.58 (25.72 to 23.45) 56</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>mUAS7,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>TABLE E1 .</head><label>E1</label><figDesc><div><p><s>Studies, treatment groups, outcomes, and time points used for meta-analysis</s></p></div></figDesc><table><row><cell>Study</cell><cell>Comparison</cell><cell>Outcome</cell><cell>Time point</cell></row><row><cell>WMD WWSs</cell><cell></cell><cell></cell><cell></cell></row><row><cell>XCUISITE</cell><cell>Omalizumab (150, 300, 600 mg) vs placebo</cell><cell>WWS from UAS7</cell><cell>Week 12</cell></row><row><cell>MYSTIQUE</cell><cell>Omalizumab (75, 300, 600 mg) vs placebo</cell><cell>WWS from mUAS7</cell><cell>Week 4</cell></row><row><cell>ASTERIA I and II</cell><cell>Omalizumab (75, 150, 300 mg) vs placebo</cell><cell>WWS from mUAS7</cell><cell>Week 12</cell></row><row><cell>GLACIAL</cell><cell>Omalizumab (300 mg) vs placebo</cell><cell>WWS from mUAS7</cell><cell>Week 12</cell></row><row><cell>MOA</cell><cell>Omalizumab (300 mg) vs placebo</cell><cell>WWS from UAS7</cell><cell>Week 12</cell></row><row><cell>X-ACT</cell><cell>Omalizumab (300 mg) vs placebo</cell><cell>WWS from mUAS7</cell><cell>Week 12</cell></row><row><cell>WMD WIS</cell><cell></cell><cell></cell><cell></cell></row><row><cell>XCUISITE</cell><cell>Omalizumab (150, 300, 600 mg) vs placebo</cell><cell>WIS from UAS7</cell><cell>Week 12</cell></row><row><cell>MYSTIQUE</cell><cell>Omalizumab (75, 300, 600 mg) vs placebo</cell><cell>WIS from mUAS7</cell><cell>Week 4</cell></row><row><cell>ASTERIA I and II</cell><cell>Omalizumab (75, 150, 300 mg) vs placebo</cell><cell>WIS from mUAS7</cell><cell>Week 12</cell></row><row><cell>GLACIAL</cell><cell>Omalizumab (300 mg) vs placebo</cell><cell>WIS from mUAS7</cell><cell>Week 12</cell></row><row><cell>MOA</cell><cell>Omalizumab (300 mg) vs placebo</cell><cell>WIS from UAS7</cell><cell>Week 12</cell></row><row><cell>X-ACT</cell><cell>Omalizumab (300 mg) vs placebo</cell><cell>WIS from mUAS7</cell><cell>Week 12</cell></row><row><cell>Responder analysis</cell><cell></cell><cell></cell><cell></cell></row><row><cell>XCUISITE</cell><cell>Omalizumab (150, 300, 600 mg) vs placebo</cell><cell>UAS7 5 0</cell><cell>Week 12</cell></row><row><cell>MYSTIQUE</cell><cell>Omalizumab (75, 300, 600 mg) vs placebo</cell><cell>mUAS7 5 0</cell><cell>Week 4</cell></row><row><cell>ASTERIA I and II</cell><cell>Omalizumab (75, 150, 300 mg) vs placebo</cell><cell>mUAS7 5 0</cell><cell>Week 12</cell></row><row><cell>GLACIAL</cell><cell>Omalizumab (300 mg) vs placebo</cell><cell>mUAS7 5 0</cell><cell>Week 12</cell></row><row><cell>MOA</cell><cell>Omalizumab (300 mg) vs placebo</cell><cell>UAS7 5 0</cell><cell>Week 12</cell></row><row><cell>X-ACT</cell><cell>Omalizumab (300 mg) vs placebo</cell><cell>mUAS7 5 0</cell><cell>Week 12</cell></row><row><cell>Safety analysis</cell><cell></cell><cell></cell><cell></cell></row><row><cell>XCUISITE</cell><cell>Omalizumab (150, 300, 600 mg) vs placebo</cell><cell>&gt; _1 AE</cell><cell>1-12</cell></row><row><cell>MYSTIQUE</cell><cell>Omalizumab (75, 300, 600 mg) vs placebo</cell><cell>&gt; _1 AE</cell><cell>1-4</cell></row><row><cell>ASTERIA I and II</cell><cell>Omalizumab (75, 150, 300 mg) vs placebo</cell><cell>&gt; _1 AE</cell><cell>1-12</cell></row><row><cell>GLACIAL</cell><cell>Omalizumab (300 mg) vs placebo</cell><cell>&gt; _1 AE</cell><cell>1-12</cell></row><row><cell>MOA</cell><cell>Omalizumab (300 mg) vs placebo</cell><cell>&gt; _1 AE</cell><cell>1-12</cell></row><row><cell>X-ACT</cell><cell>Omalizumab (300 mg) vs placebo</cell><cell>&gt; _1 AE</cell><cell>1-12</cell></row></table><note><p><s>mUAS7, Modified UAS7.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOL VOLUME 137, NUMBER 6</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>We thank Nadine Chapman-Rothe and Veit Erpenbeck (both from Novartis) for providing data from the X-ACT and MOA trial, respectively.</s></p><p><s>Clinical implications: Results of this meta-analysis support the recommendation for treatment of CSU at the standard dose of 300 mg every 4 weeks.</s><s>Omalizumab is well tolerated by patients with CSU in doses of up to 600 mg every 4 weeks.</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gimenez-Arnau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="317" to="330" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Chronic idiopathic urticaria and Graves&apos; disease</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Ruggeri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Imbesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saitta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Campenni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cannavo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Trimarchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Endocrinol Invest</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="531" to="536" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Brzoza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Canonica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="868" to="887" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Disease activity only moderately correlates with quality of life impairment in patients with chronic spontaneous urticaria</title>
		<author>
			<persName><forename type="first">I</forename><surname>Koti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Makris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tiligada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Psaltopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Papageorgiou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatology</title>
		<imprint>
			<biblScope unit="volume">226</biblScope>
			<biblScope unit="page" from="371" to="379" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Current challenges and controversies in the management of chronic spontaneous urticaria</title>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pinter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Marra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tedeschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cugno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Marzano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1073" to="1082" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients</title>
		<author>
			<persName><forename type="first">E</forename><surname>Toubi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kessel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Avshovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bamberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sabo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nusem</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="869" to="873" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Management and treatment of chronic urticaria (CU)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Goncalo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sussman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sanchez-Borges</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="16" to="32" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Structural and physical basis for anti-IgE therapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wen</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Rep</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">11581</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Omalizumab-induced reductions in mast cell Fce psilon RI expression and function</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Marcotte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Macglashan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Togias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="527" to="530" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Effect of omalizumab on patients with chronic urticaria</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Spector</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Tan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="190" to="193" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab</title>
		<author>
			<persName><forename type="first">C</forename><surname>Vestergaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Deleuran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="443" to="444" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab</title>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ardelean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="665" to="666" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mendes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Barbosa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergol Immunopathol (Madr)</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="168" to="173" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The figure shows the contribution of results from the patient groups treated with different doses of omalizumab in the different studies to the heterogeneity of efficacy of treatment. The group receiving 75 mg of omalizumab in the ASTERIA II study was found to be the main cause of the heterogeneity. ASI75, ASTERIA I 75 mg; ASI150, ASTERIA I 150 mg</title>
	</analytic>
	<monogr>
		<title level="m">FIG 5. Galbraith radial plot</title>
				<imprint>
			<biblScope unit="volume">300</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">II 75 mg</title>
		<author>
			<persName><forename type="first">Asteria</forename><surname>Asii75</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">GLACIAL</title>
		<imprint>
			<biblScope unit="volume">300</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">MOA 300 mg</title>
	</analytic>
	<monogr>
		<title level="m">MOA300</title>
				<imprint>
			<biblScope unit="volume">75</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
	</analytic>
	<monogr>
		<title level="m">MY300</title>
				<imprint>
			<biblScope unit="volume">300</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
	</analytic>
	<monogr>
		<title level="m">MY600</title>
				<imprint>
			<biblScope unit="volume">600</biblScope>
		</imprint>
	</monogr>
	<note>MYSTQUE</note>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title level="m">XC300, XCUISITE 300 mg; XC600, XCUISITE 600 mg</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Viswanathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Mathur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Proc</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="446" to="452" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Omalizumab in chronic urticaria: a retrospective series of 15 cases</title>
		<author>
			<persName><forename type="first">M</forename><surname>Armengot-Carbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Velasco-Pastor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rodrigo-Nicolas</forename></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pont-Sanjuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Quecedo-Estebanez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gimeno-Carpio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatol Ther</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="257" to="259" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Treatment of chronic autoimmune urticaria with omalizumab</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Joseph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Maykut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Geba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Zeldin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="569" to="573" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bieber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Biedermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brautigam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Seyfried</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="202" to="209" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>e5</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria</title>
		<author>
			<persName><forename type="first">S</forename><surname>Saini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Conner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kaplan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="567" to="573" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>e1</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Grattan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gimenez-Arnau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="924" to="935" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ledford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ashby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Canvin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Zazzali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Conner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="101" to="109" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Efficacy and safety of omalizumab in patients with chronic idiopathic/ spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Saini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Grob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bulbul</forename><surname>Baskan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bradley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page">925</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Urgert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Van Den Elzen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Knulst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Fedorowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Van Zuuren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">173</biblScope>
			<biblScope unit="page" from="404" to="415" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Quantifying heterogeneity in a meta-analysis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Thompson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1539" to="1558" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased</title>
		<author>
			<persName><forename type="first">L</forename><surname>Irwig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Macaskill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Berry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Glasziou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">316</biblScope>
			<biblScope unit="page">471</biblScope>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Stuck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Z</forename><surname>Rubenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wieland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">316</biblScope>
			<biblScope unit="page" from="470" to="471" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">The Cochrane Collaboration&apos;s tool for assessing risk of bias in randomised trials</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Gotzsche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Juni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Moher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="page">5928</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title level="m" type="main">Effect of omalizumab on angioedema in H1-antihistamine resistant chronic spontaneous urticaria patients: results from X-ACT</title>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Chapman-Rothe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sieder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Br€ Autigam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Canvin</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2016-03-24">2016 Mar 24</date>
		</imprint>
	</monogr>
	<note>E-pub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Omalizumab normalizes levels of high affinity immunoglobulin E receptor-positive skin mast cells in patients with chronic spontaneous urticaria: a randomized, double-blind, placebo-controlled study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Brehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gericke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ashton-Chess</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="S30" to="38" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title level="m" type="main">Subgroup analysis of time point. A, WIS. B, Weekly hive score. C, Number of complete responders</title>
		<author>
			<persName><surname>Fig E1</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<title level="m" type="main">At least 1 AE. Horizontal lines represent 95% CIs of the RR estimates. Diamonds represent the meta-analysis summary effect estimate; green dots represent the WMD</title>
		<imprint/>
	</monogr>
	<note>and blue dots represent the RR</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
